Trial Profile
Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs BCT 100 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 15 Apr 2021 Results (n=27) from phase II portion of the trial published in the Investigational New Drugs
- 13 Mar 2012 Actual end date (February 2012) added as reported by ClinicalTrials.gov.
- 13 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.